Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review

“…Also, the place of the second and third generation TKI's (EGFR: afatinib, AZD9291, CO-1686, ALK: ceritinib, alectinib) should be determined as these agents have a better penetration in the CSF compared to first generation TKI's and cranial responses are found with these agents in patients who develop brain metastases when they have already been treated with first generation TKI [15,[60][61][62]. Another option that could be explored in this patient population is the use of SRS without WBRT, even for multiple (five to ten) brain metastases.…”

Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non–Small-Cell Lung Cancer

“…Tumor shrinkage was observed in 50.0% of patients (95% CI, 39.7%-60.3%) with brain metastases who had received a previous ALK inhibitor and 69.2% of brain metastases patients (95% CI, 48.2%-85.7%) who had not. 34 Although these data are "immature," the marked response to ceritinib has demonstrated a clinically meaningful effect on brain metastases of ALK-positive NSCLC.…”

“…3 In addition, the results of a phase I, singlearm study of ceritinib were updated by Kim et al at the 2014 American Society of Clinical Oncology Annual Meeting. 34 Among 124 patients with initial brain metastases, use of ceritinib (750 mg daily) achieved an ORR of 54.0% (95% CI, 44.9%-63.0%) and a median PFS of 6.9 months (95% CI, 5.4-8.4). Tumor shrinkage was observed in 50.0% of patients (95% CI, 39.7%-60.3%) with brain metastases who had received a previous ALK inhibitor and 69.2% of brain metastases patients (95% CI, 48.2%-85.7%) who had not.…”

Future options for ALK-positive non-small cell lung cancer

“…At ASCO 2014, updated data were presented on 246 patients treated at 750 mg daily with 4.5 months of median follow-up [46]. Eighty-three patients were crizotinib-naïve while 163 had received prior crizotinib.…”